Vioxx award spells big trouble for Merck

Virtually every legal analyst agrees that the bulk of Friday's enormous $253 million award against Merck won't withstand an appeal. Texas law severely limits punitive damages. On the other hand, a host of analysts were also in agreement that the jury award represents a bitter pill for the drug maker. Thousands of lawsuits have already been filed against Merck, and now many more may be inspired as lawyers and plaintiffs respond to the jury's conclusion that the drug company knew Vioxx was dangerous and hid that fact from the public. Merck's stock lost 8 percent in value on Friday afternoon as the news began to sink in.

- read this article from The New York Times for more

Suggested Articles

One day after its Opdivo-paired prospect flopped, Five Prime is farming out some preclinical antibodies to keep its clinical-stage pipeline alive.

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.